Mediwound

MDWD · NASDAQ

$12.10−$0.60 (−4.72%)TodayMarket closed ·
Prev close $12.70

Key indicators

MDWD profitability and balance sheet ratios

EPS -$0.5737 in Jun 2026, against -$1.23 a year earlier.

EPS by quarter
PeriodEPS
Sep 2024-$0.9091
Dec 2024-$0.3618
Mar 2025-$0.0672
Jun 2025-$1.23
Sep 2025-$0.2406
Dec 2025-$0.5591
Mar 2026-$0.2293
Jun 2026-$0.5737

Where the money went

Q4 FY15, from revenue to net income

Mediwound brought in $0.3M of revenue in Q4 FY15, +115.3% on a year earlier. It made a net loss of $7.8M.

Revenue
$0.3M
Costs, expenses and taxes
$8.0M
Net income
−$7.8M
Net margin
-2913.9%

Income statement

Revenue and profit by reporting period

Revenue
Net income
MDWD income statement, quarterly
Line itemQ1 FY15Q3 FY15Q4 FY15
Revenue$0.1M$0.1M$0.3M
Gross profit−$0.1M−$0.7M−$0.4M
Operating income−$4.5M−$4.4M−$6.8M
Net income−$6.4M−$3.8M−$7.8M
Diluted EPS-$2.10-$1.19-$2.52

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
MDWD balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$86.3M$80.0M$71.9M
Total liabilities$42.6M$38.6M$36.2M
Shareholder equity$43.6M$41.4M$35.6M
Cash and short-term investments$53.1M$44.6M$35.3M
Total debt$8.2M$8.1M$8.6M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
MDWD cash flow, quarterly
Line itemQ1 FY15Q3 FY15Q4 FY15
Operating cash flow−$4.8M−$5.3M−$4.9M
Investing cash flow−$3.0M$16.0M$22.1M
Financing cash flow—$0.0M$0.6M
Capital expenditure−$0.1M−$0.1M−$0.1M
Free cash flow−$4.8M−$5.4M−$5.0M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.